Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Big readouts ahead for small biotechs
Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Big biotech's upcoming clinical priorities
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Approaching datasets for big pharma
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.